Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Receivables: 2009-2024

Historic Receivables for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $279.3 million.

  • UNITED THERAPEUTICS's Receivables fell 12.90% to $297.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 4.89%. This contributed to the annual value of $279.3 million for FY2024, which is 0.14% up from last year.
  • According to the latest figures from FY2024, UNITED THERAPEUTICS's Receivables is $279.3 million, which was up 0.14% from $278.9 million recorded in FY2023.
  • In the past 5 years, UNITED THERAPEUTICS's Receivables ranged from a high of $279.3 million in FY2024 and a low of $157.4 million during FY2020.
  • For the 3-year period, UNITED THERAPEUTICS's Receivables averaged around $259.5 million, with its median value being $278.9 million (2023).
  • Data for UNITED THERAPEUTICS's Receivables shows a peak YoY climbed of 26.54% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows UNITED THERAPEUTICS's Receivables stood at $157.4 million in 2020, then grew by 26.24% to $198.7 million in 2021, then rose by 10.92% to $220.4 million in 2022, then rose by 26.54% to $278.9 million in 2023, then climbed by 0.14% to $279.3 million in 2024.